Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.42 |
| ▸ | MPO | P05164 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | NQO2 | P16083 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27367756 | 0.94 | HTR2A (0.47) | HTR2AMTNR1AMTNR1BMPOHTR2C | |
| Fumaric Acid SCHEMBL31331788 | 0.89 | HTR2A (0.46) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL31618132 | 0.89 | HTR2A (0.52) | HTR2AMTNR1AMTNR1BMPOHTR2C | |
| SCHEMBL27366183 | 0.85 | HTR2A (0.64) | HTR2AMTNR1AMTNR1BMPOHTR6 | |
| SCHEMBL27365895 | 0.83 | HTR2A (0.59) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL27367754 | 0.83 | HTR2A (0.52) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL31332043 | 0.82 | HTR2A (0.58) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL27366114 | 0.82 | HTR2A (0.60) | HTR2AMTNR1AHTR2CHTR2BNQO2 | |
| SCHEMBL27366184 | 0.81 | HTR2A (0.67) | HTR2AMTNR1AMTNR1BMPOHTR2C | |
| SCHEMBL27365826 | 0.81 | HTR2A (0.75) | HTR2AMTNR1AMTNR1BHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333371-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-10-30 | — | — | US | disclosed |
| EP-4532462-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-04-09 | — | — | EP | disclosed |
| CN-119384406-A | Compounds of formula (I) | 赛洛私人有限公司 | 2025-01-28 | — | — | CN | disclosed |
| WO-2023230649-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333371-A1 | COMPOUNDS | SDHA, PYGB, SLC18A2 | HTR2A 225/4885MTNR1A 1247/4885MTNR1B 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.